
|Videos|February 8, 2022
Dr. Kishan calls for more prospective studies on the predictive nature of germline variants
Author(s)Urology Times staff
“What really needs to be done to show that this works is to look prospectively,” says Amar U. Kishan, MD.
Advertisement
In this video, Amar U. Kishan, MD, discusses the takeaways of the study, “Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.” Kishan is an associate professor in the department of radiation oncology, chief of genitourinary oncology service, and vice chair of clinical and translational research at the University of California, Los Angeles.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA updates in urology: May 2026
4
FDA approves cefepime and zidebactam for complicated UTI
5











